Driving research of Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS),
Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia and Long Covid

OMF-finansierad forskning: Röda blodkroppars förmåga att ändra form vid ME / CFS

Denna #OMFScienceWednesday presenterar vi ett nytt projekt finansierat av OMF som kommer att utvärdera röda blodkroppars förmåga att ändra form som en potentiell biomarkör för ME / CFS.

Röda blodkroppar är de vanligaste cellerna i blodet. Deras främsta uppgift är att transportera syre och koldioxid i blodet och den uppgiften är delvis beroende av deras förmåga att ändra form/tänjbarhet när de passerar genom små blodkärl. Förändringar i de röda blodkropparnas förmåga att ändra form har kopplats till inflammation och sjukdomar som sepsis och vissa studier tyder på att skador på de röda blodkropparna förekommer vid ME / CFS. Dessa observationer och att det nu finns ny teknologi för att mäta röda blodkroppars formbarhetsförmåga, föranledde dr Ron Davis team vid Stanford och deras samarbetspartners vid San Jose State University att undersöka röda blodkroppars formbarhet vid ME / CFS.

I mycket tidig data genererad av teamet finns indikationer på att förmågan att ändra form hos röda blodkroppar är nedsatt hos vissa ME / CFS-patienter. Enligt tester med den nya tekniken verkar ME / CFS-blodkropparna som undersökts hittills röra sig saktare och bli mindre långsträckta än de från friska kontroller. Vi finansierar ett projekt för att kunna bekräfta dessa fynd hos ytterligare patienter och för att studera röda blodkroppar med flera metoder, inklusive olika typer av avancerad mikroskopi, för att bättre förstå varför dessa skillnader existerar.

Om dessa experiment blir lyckade kan de skapa en ny biomarkör för ME / CFS som skulle kunna hjälpa  vid diagnosticering och kanske också med att hitta nya behandlingar! Mer information i kommande inlägg.

Mer om röda blodkroppar i denna video från Khan Academy:

https://www.youtube.com/watch?v=fLKOBQ6cZHA

OMF tackar Lotta Hahn för den svenska översättningen

Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS) Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia Leading Research. Delivering Hope.Open Medicine Foundation®

What are the advantages of giving from your Donor Advised Fund (DAF)?

  • Your gifts to your donor advised fund entitle you to an immediate income tax deduction at the time of contribution.
  • You avoid capital gains tax on appreciated assets you place in your donor advised fund.
  • Your fund’s investment gains accumulate tax free.
  • Funds are distributed to Open Medicine Foundation in your name and immediately put to use to support our worldwide research efforts.

How do I make a donation through my DAF?

Just click on the DAF widget below. It is simple and convenient to find your fund among the over 900 funds in our system.

Still can’t find your fund? 

  • Request a grant distribution through your Donor Advised Fund sponsor
  • Be sure to use OMF’s EIN #26-4712664
  • You can also designate OMF as a beneficiary for your Donor Advised Fund
  • Questions? Give us a call at 650-242-8669 

Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS) Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia Leading Research. Delivering Hope.Open Medicine Foundation®

Averting a second pandemic:

Open Medicine Foundation leads groundbreaking international study of

Long COVID’s conversion to ME/CFS

AGOURA HILLS, CALIF.  — Open Medicine Foundation (OMF) is leading a large-scale international collaborative study investigating the potential conversion of Post-Acute Sequelae SARS-CoV-2 infection — more commonly known as Long COVID or Post-COVID Syndrome —  to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a chronic, life-altering disease with no known cause, diagnostic test or FDA approved treatments available.

Up to 2.5 million people in the U.S. alone suffer from ME/CFS; the COVID-19 pandemic could at least double that number. An estimated 35 percent of Americans who had COVID-19 have failed to fully recover several months after infection, prompting many to call it “a potential second pandemic.”

OMF recognized a familiar health crisis emerging, one with eerie similarities to ME/CFS. This crisis presented a unique opportunity to understand how a viral infection — in this case COVID-19 — may develop into ME/CFS in some patients. The goal is to find targeted treatments for ME/CFS patients and ultimately prevent its onset in people infected with SARS-CoV-2 or other infections.

The federal government is only now investing in Post-COVID research, with no focus on its connection to ME/CFS. OMF has already engaged researchers for the largest-scale study of its kind, solely supported by private donors who have contributed over one million dollars to date. When fully funded, the five million dollar, three-year study will be conducted across the globe at OMF funded Collaborative Research Centers, led by some of the world’s top researchers and ME/CFS experts.

BACKGROUND

In a significant percentage of patients, infections preceded their development of ME/CFS.  For example, according to the CDC about one in ten infected with Epstein-Barr virus, Ross River virus, or Coxiella burnetti develop symptoms that meet the criteria for ME/CFS.

THE STUDY

The ability to follow the development of ME/CFS from a known viral infection is unprecedented to date and crucial to researchers’ understanding of the disease. The focus of this study is to find the biological differences between persons returning to good health after COVID-19 and persons who remained ill more than six months after infection and developed ME/CFS.  Understanding these alterations in key pathways can lead to groundbreaking discoveries including new biomarkers, drug targets, and prevention and treatment strategies.

###

About Open Medicine Foundation

Established in 2012, Open Medicine Foundation leads the largest, concerted worldwide nonprofit effort to diagnose, treat, and prevent ME/CFS and related chronic, complex diseases such as Post Treatment Lyme Disease Syndrome, Fibromyalgia, and Post COVID. OMF adds urgency to the search for answers by driving transformational philanthropy into global research. We have raised over $28 Million from private donors and facilitated and funded the establishment of six prestigious ME/CFS Collaborative Research Centers around the world. To learn more, visit www.omf.ngo.

CONTACT:

Heather Ah San

Development and Communications Manager

1-650-242-8669

heather@omf.ngo